Celldex Therapeutics, Inc.
CLDX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $1,627,262 | $1,921,487 | $2,089,798 | $1,656,497 |
| - Cash | $28,356 | $34,814 | $29,429 | $39,143 |
| + Debt | $3,813 | $2,542 | $4,033 | $3,042 |
| Enterprise Value | $1,602,719 | $1,889,215 | $2,064,402 | $1,620,396 |
| Revenue | $7,020 | $6,883 | $2,357 | $4,651 |
| % Growth | 2% | 192% | -49.3% | – |
| Gross Profit | -$156,530 | -$111,128 | -$79,901 | -$48,660 |
| % Margin | -2,229.8% | -1,614.5% | -3,389.9% | -1,046.2% |
| EBITDA | -$191,901 | -$139,034 | -$104,200 | -$66,080 |
| % Margin | -2,733.6% | -2,020% | -4,420.9% | -1,420.8% |
| Net Income | -$157,863 | -$141,429 | -$112,325 | -$70,511 |
| % Margin | -2,248.8% | -2,054.8% | -4,765.6% | -1,516% |
| EPS Diluted | -2.45 | -2.92 | -2.4 | -1.64 |
| % Growth | 16.1% | -21.7% | -46.3% | – |
| Operating Cash Flow | -$157,778 | -$107,291 | -$103,732 | -$60,909 |
| Capital Expenditures | -$1,919 | -$1,818 | -$1,828 | -$1,249 |
| Free Cash Flow | -$159,697 | -$109,109 | -$105,560 | -$62,158 |